GetTopicDetailResponse(id=5c081e1621c, topicName=TAVO, introduction=TAVO, content=null, image=null, comments=2, allHits=927, url=https://h5.medsci.cn/topic?id=17162, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=103189, tagList=[TagDto(tagId=103189, tagName=TAVO)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2077012, encodeId=957a20e7012e4, content=<a href='/topic/show?id=5c081e1621c' target=_blank style='color:#2F92EE;'>#TAVO#</a>, objectTitle=TAVO聯(lián)合OPDIVO作為黑色素瘤的新型輔助療法：II期試驗(yàn)中患者首次給藥, objectType=article, longId=205631, objectId=e7872056314a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7872056314a, replyNumber=0, likeNumber=133, createdTime=2021-10-07, rootId=0, userName=12498761m56暫無昵稱, userId=b78f2500065, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7872056314a, moduleTitle=TAVO聯(lián)合OPDIVO作為黑色素瘤的新型輔助療法：II期試驗(yàn)中患者首次給藥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e7872056314a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077011, encodeId=6f1020e701167, content=<a href='/topic/show?id=5c081e1621c' target=_blank style='color:#2F92EE;'>#TAVO#</a>, objectTitle=TAVO聯(lián)合KEYTRUDA治療晚期轉(zhuǎn)移性黑素瘤：總緩解率達(dá)41％，完全緩解率達(dá)36％, objectType=article, longId=193651, objectId=96f61936511b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96f61936511b, replyNumber=0, likeNumber=74, createdTime=2020-08-22, rootId=0, userName=12498761m56暫無昵稱, userId=b78f2500065, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96f61936511b, moduleTitle=TAVO聯(lián)合KEYTRUDA治療晚期轉(zhuǎn)移性黑素瘤：總緩解率達(dá)41％，完全緩解率達(dá)36％, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=96f61936511b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
